A pan-Canadian randomzied controlled trial of an ARB (losartan) vs. usual care and mortality of COVID-19. Evaluation of ACE pathway proteins, proteomics and metabolomics as biomarkes of response to losartan and outome of COVID-19.
More details on the clinical trial can be found here.
Related publications from ARBS CORONA I:
- Best JR et al. Early increases in anti-SARS-CoV-2 antibody isotypes associated with organ dysfunction and mortality in patients hospitalized with COVID-19.
Intensive Care Med. 2022 May;48(5):616-618. doi: 10.1007/s00134-022-06662-9.
-
Mohammed Y et al. Longitudinal Plasma Proteomics Analysis Reveals Novel Candidate Biomarkers in Acute COVID-19. J Proteome Res. 2022 Apr 1;21(4):975-992. doi: 10.1021/acs.jproteome.1c00863.
-
Cheng MP et al. Acute Cardiac Injury in Coronavirus Disease 2019 and Other Viral Infections-A Systematic Review and Meta-Analysis. Crit Care Med. 2021 Sep 1;49(9):1558-1566. doi: 10.1097/CCM.0000000000005026.
-
Lee T et al. Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in COVID-19: Meta-analysis/Meta-regression Adjusted for Confounding Factors. CJC Open. 2021 Jul;3(7):965-975. doi: 10.1016/j.cjco.2021.03.001. Epub 2021 Apr 6.
-
Lee T et al. Organ dysfunction and death in patients admitted to hospital with COVID-19 in pandemic waves 1 to 3 in British Columbia, Ontario and Quebec, Canada: a cohort study. CMAJ Open. 2022 Apr 19;10(2):E379-E389. doi: 10.9778/cmajo.20210216